|
1
|
Mansoori B, Mohammadi A, Ghasabi M,
Shirjang S, Dehghan R, Montazeri V, Holmskov U, Kazemi T, Duijf P,
Gjerstorff M and Baradaran B: miR-142-3p as tumor suppressor miRNA
in the regulation of tumorigenicity, invasion and migration of
human breast cancer by targeting Bach-1 expression. J Cell Physiol.
234:9816–9825. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017, racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giovannelli P, Di Donato M, Galasso G, Di
Zazzo E, Bilancio A and Migliaccio A: The androgen receptor in
breast cancer. Front Endocrinol (Lausanne). 9:4922018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Domschke C, Schneeweiss A, Stefanovic S,
Wallwiener M, Heil J, Rom J, Sohn C, Beckhove P and Schuetz F:
Cellular immune responses and immune escape mechanisms in breast
cancer: Determinants of immunotherapy. Breast Care (Basel).
11:102–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mittal D, Gubin MM, Schreiber RD and Smyth
MJ: New insights into cancer immunoediting and its three component
phases-elimination, equilibrium and escape. Curr Opin Immunol.
27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mizukami Y, Kono K, Kawaguchi Y, Akaike H,
Kamimura K, Sugai H and Fujii H: CCL17 and CCL22 chemokines within
tumor microenvironment are related to accumulation of
Foxp3+ regulatory T cells in gastric cancer. Int J
Cancer. 122:2286–2293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu C, Workman CJ and Vignali DA:
Targeting regulatory T cells in tumors. FEBS J. 283:2731–2748.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Liu X, Wang W, Wang S, Zhang J,
Jiang S, Wang Y, Li L, Li J, Zhang Y and Huang H: Low-dose IL-2
expands CD4+ regulatory T cells with a suppressive
function in vitro via the STAT5-dependent pathway in patients with
chronic kidney diseases. Ren Fail. 40:280–288. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roychoudhuri R, Eil RL and Restifo NP: The
interplay of effector and regulatory T cells in cancer. Curr Opin
Immunol. 33:101–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
DeNardo DG and Coussens LM: Inflammation
and breast cancer. Balancing immune response: Crosstalk between
adaptive and innate immune cells during breast cancer progression.
Breast Cancer Res. 9:2122007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Plitas G, Konopacki C, Wu K, Bos PD,
Morrow M, Putintseva EV, Chudakov DM and Rudensky AY: Regulatory T
cells exhibit distinct features in human breast cancer. Immunity.
45:1122–1134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugiyama D, Nishikawa H, Maeda Y, Nishioka
M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y,
et al: Anti-CCR4 mAb selectively depletes effector-type
FoxP3+CD4+ regulatory T cells, evoking
antitumor immune responses in humans. Proc Natl Acad Sci USA.
110:17945–17950. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thornton AM, Donovan EE, Piccirillo CA and
Shevach EM: Cutting edge: IL-2 is critically required for the in
vitro activation of CD4+CD25+ T cell
suppressor function. J Immunol. 172:6519–6523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang TT, Song SJ, Xue HB, Shi DF, Liu CM
and Liu H: Regulatory T cells in the pathogenesis of type 2
diabetes mellitus retinopathy by miR-155. Eur Rev Med Pharmacol
Sci. 19:2010–2015. 2015.PubMed/NCBI
|
|
17
|
Hippen KL, Merkel SC, Schirm DK, Sieben
CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL,
Riley JL, et al: Massive ex vivo expansion of human natural
regulatory T cells (T(regs)) with minimal loss of in vivo
functional activity. Sci Transl Med. 3:83ra412011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu L, Zhou X, Wang J, Zheng SG and Horwitz
DA: Characterization of protective human CD4CD25 FOXP3 regulatory T
cells generated with IL-2, TGF-β and retinoic acid. PLoS One.
5:e151502010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu H, Wang SH, Chen SC, Chen CY and Lin
TM: Zoledronic acid blocks the interaction between breast cancer
cells and regulatory T-cells. BMC Cancer. 19:1762019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Higuchi T, Matsuo K, Hashida Y, Kitahata
K, Ujihara T, Taniguchi A, Yoshie O, Nakayama T and Daibata M:
Epstein-Barr virus-positive pyothorax-associated lymphoma expresses
CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory
T cells. Cancer Lett. 453:184–192. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xing Y, Tian Y, Kurosawa T, Matsui S,
Touma M, Yanai T, Wu Q and Sugimoto K: CCL11-induced eosinophils
inhibit the formation of blood vessels and cause tumor necrosis.
Genes Cells. 21:624–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang J, Hawkins OE, Barham W, Gilchuk P,
Boothby M, Ayers GD, Joyce S, Karin M, Yull FE and Richmond A:
Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and
the innate immune response. Cancer Res. 74:7274–7284. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Venet F, Lepape A, Debard AL, Bienvenu J,
Bohe J and Monneret G: The Th2 response as monitored by CRTH2 or
CCR3 expression is severely decreased during septic shock. Clin
Immunol. 113:278–284. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gonzalez Rivas E, Ximenez C,
Nieves-Ramirez ME, Moran Silva P, Partida-Rodríguez O, Hernandez
EH, Rojas Velázquez L, Serrano Vázquez A and Magaña Nuñez U:
Entamoeba histolytica calreticulin induces the expression of
cytokines in peripheral blood mononuclear cells isolated from
patients with amebic liver abscess. Front Cell Infect Microbiol.
8:3582018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pinho V, Oliveira SH, Souza DG,
Vasconcelos D, Alessandri AL, Lukacs NW and Teixeira MM: The role
of CCL22 (MDC) for the recruitment of eosinophils during allergic
pleurisy in mice. J Leukocyte Biol. 73:356–362. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Liu M, Ding N, Li Y, Shao J, Zhu
M, Xie Z and Sun K: Vaccine based on antibody-dependent
cell-mediated cytotoxicity epitope on the H1N1 influenza virus
increases mortality in vaccinated mice. Biochem Biophys Res Commun.
503:1874–1879. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clark-Knowles KV, Dewar-Darch D, Jardine
KE and McBurney MW: SIRT1 catalytic activity has little effect on
tumor formation and metastases in a mouse model of breast cancer.
PLoS One. 8:e821062013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rani A and Murphy JJ: STAT5 in cancer and
immunity. J Interferon Cytokine Res. 36:226–237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldstein JD, Burlion A, Zaragoza B,
Sendeyo K, Polansky JK, Huehn J, Piaggio E, Salomon BL and Marodon
G: Inhibition of the JAK/STAT signaling pathway in regulatory T
cells reveals a very dynamic regulation of Foxp3 expression. PLoS
One. 11:e01536822016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Janssen E, Kumari S, Tohme M, Ullas S,
Barrera V, Tas JM, Castillo-Rama M, Bronson RT, Usmani SM, Irvine
DJ, et al: DOCK8 enforces immunological tolerance by promoting IL-2
signaling and immune synapse formation in Tregs. JCI insight.
2(pii): 942982017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ramos RN, Chin LS, Dos Santos AP,
Bergami-Santos PC, Laginha F and Barbuto JA: Monocyte-derived
dendritic cells from breast cancer patients are biased to induce
CD4+CD25+Foxp3+ regulatory T
cells. J Leukocyte Biol. 92:673–682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu F, Lang R, Zhao J, Zhang X, Pringle
GA, Fan Y, Yin D, Gu F, Yao Z and Fu L: CD8+ cytotoxic T
cell and FOXP3+ regulatory T cell infiltration in
relation to breast cancer survival and molecular subtypes. Breast
Cancer Res Treat. 130:645–655. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yeong J, Thike AA, Lim JC, Lee B, Li H,
Wong SC, Hue SS, Tan PH and Iqbal J: Higher densities of
Foxp3+ regulatory T cells are associated with better
prognosis in triple-negative breast cancer. Breast Cancer Res
Treat. 163:21–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Levina V, Nolen BM, Marrangoni AM, Cheng
P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E and Lokshin AE:
Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res.
15:2647–2656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu F, Liu P, Li J and Zhang Y: Eotaxin-1
promotes prostate cancer cell invasion via activation of the
CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol Rep.
31:2049–2054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miyagaki T, Sugaya M, Murakami T, Asano Y,
Tada Y, Kadono T, Okochi H, Tamaki K and Sato S: CCL11-CCR3
interactions promote survival of anaplastic large cell lymphoma
cells via ERK1/2 activation. Cancer Res. 71:2056–2065. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ni X, Kou W, Gu J, Wei P, Wu X, Peng H,
Tao J, Yan W, Yang X, Lebid A, et al: TRAF6 directs FOXP3
localization and facilitates regulatory T-cell function through
K63-linked ubiquitination. EMBO J. 38(pii): e997662019.PubMed/NCBI
|
|
38
|
Kagoya Y, Saijo H, Matsunaga Y, Guo T,
Saso K, Anczurowski M, Wang CH, Sugata K, Murata K, Butler MO, et
al: Arginine methylation of FOXP3 is crucial for the suppressive
function of regulatory T cells. J Autoimmun. 97:10–21. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ren L, Yu Y, Wang L, Zhu Z, Lu R and Yao
Z: Hypoxia-induced CCL28 promotes recruitment of regulatory T cells
and tumor growth in liver cancer. Oncotarget. 7:75763–75773. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mahmud SA, Manlove LS and Farrar MA:
Interleukin-2 and STAT5 in regulatory T cell development and
function. JAKSTAT. 2:e231542013.PubMed/NCBI
|
|
41
|
Horwitz DA, Zheng SG, Wang J and Gray JD:
Critical role of IL-2 and TGF-beta in generation, function and
stabilization of Foxp3+CD4+ Treg. Eur J
Immunol. 38:912–915. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zorn E, Nelson EA, Mohseni M, Porcheray F,
Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ,
et al: IL-2 regulates FOXP3 expression in human
CD4+CD25+ regulatory T cells through a
STAT-dependent mechanism and induces the expansion of these cells
in vivo. Blood. 108:1571–1579. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stevenson NJ, Addley MR, Ryan EJ, Boyd CR,
Carroll HP, Paunovic V, Bursill CA, Miller HC, Channon KM, McClurg
AE, et al: CCL11 blocks IL-4 and GM-CSF signaling in hematopoietic
cells and hinders dendritic cell differentiation via suppressor of
cytokine signaling expression. J Leukocyte Biol. 85:289–297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
